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ABSTRACT
EFFECTS OF PREBIOTICS ON GUT BACTERIAL COMMUNITIES AND
HEALING OF INDUCED COLITIS IN MICE
by Krystyn Elizabeth Davis
August 2016
Inflammatory Bowel Diseases (IBD) cause chronic inflammation of the
gastrointestinal tract and debilitating symptoms in those suffering from the
diseases. After inducing colitis in a mouse model using Dextran Sulfate Sodium
(DSS), prebiotics inulin and oligofructose enriched inulin (OEI) were used as
treatments to determine their effects on the gut microbial community,
physiological healing process, and immune response in the mice after initial
inflammation and before subsequent inflammation, or relapse. The treatment with
inulin led to an increase in regulatory T cell number, but this increase was not as
significant as the increase induced by the OEI. Inulin increased the inflammation
in the mouse colon, whereas inflammation was decreased in the colons of the
mice treated with OEI. A three percent increase in butyrate producing bacteria,
Clostridium cluster XIVa spp., was observed in mice treated with OEI before the
relapse period when compared to untreated mice with colitis. The proposed
mechanism for how the OEI led to decreased inflammation in the colons of the
treated mice was that the introduction of the prebiotic allowed for an increase in
butyrate producing Clostridium cluster XIVa spp., which led to a direct increase in
butyrate production in the colon. In turn, this butyrate production led to an
ii

increase in differentiation of regulatory T cells and an overall reduction of the
immune response and inflammation in the mice treated with OEI. This reduction
of immune response and inflammation allowed the mice that were treated with
OEI to be more resistant to induced relapse.
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CHAPTER I - INTRODUCTION
Inflammatory Bowel Diseases (IBD) cause chronic inflammation of the
gastrointestinal tract. The two major forms of IBD are Crohn’s disease and
ulcerative colitis. Crohn’s disease may affect any part of the gastrointestinal tract
including every layer of the intestine. Ulcerative colitis, however, only takes place
in the colon. The diseases may consist of remission periods when one
experiences no symptoms, followed by “flare-ups” where debilitating symptoms
such as weight loss, severe abdominal pain, rectal bleeding, vomiting, and
diarrhea may be experienced. These random “flare-ups” are what make the
diseases so frustrating and hard to study and treat. Although these diseases are
rarely fatal, they can severely affect a person’s quality of life in a negative way.
As of the year 2014, IBD was shown to account for more than 700,000 physician
visits, 100,000 hospitalizations, and disability in 199,000 patients yearly in the
United States alone, and had an overall health care cost of over $1.7 billion
(Centers for Disease Control and Prevention [CDC], 2014).
During IBD, the immune system mistakes normal intestinal components
for foreign or pathogenic substances. This causes an immunological response
that leads to chronic inflammation. The cause of this occurrence is largely
unknown. However, several factors have been found to contribute to the
development of the disease. One major factor that has gained increasing
interest is the host’s gut microbial community. A number of studies suggest that
gut microbiota must play a role in the cause and development of IBD. According
to Swidsinski et al. (2002), colon inflammation tends to occur in segments with
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the highest concentrations of bacteria associated with the mucosa. Bibiloni,
Mangold, Madsen, Fedorak, and Tannock (2006) found that patients with IBD
contained atypical intestinal microbial composition. According to D’Haens et al.
(1998), diversion of the fecal stream treats some forms of IBD, and intestinal
inflammation returns upon the reintroduction of the fecal stream. Also, Sartor
(2006) mentions that luminal commensal bacteria are required for chronic
inflammation in most rodent models of IBD. In summary, multiple studies have
provided evidence that gut microbiota may play a major role in the onset of the
disease. However, it is still largely unknown as to why or how this occurs.
There are several theories on why gut microbes are involved in the
pathogenesis of IBD. One theory is that microbial pathogens cause intestinal
inflammation. These pathogens may include traditional pathogens such as
Mycobacterium avium subspecies paratuberculosis, or they may include
commensal bacteria such as Escherichia coli or Staphylococcus aureus that
have been altered functionally (Sartor, 2008). The second is the idea that host
immunoregulation does not function properly during the disease (Sartor, 2008).
In other words, the host has lost the ability to distinguish between beneficial and
pathogenic bacteria and has begun attacking all gut bacteria, which causes an
overaggressive immune response and subsequent inflammation. A third theory is
that the dysbiosis of gut microbiota causes the disease (Sartor, 2008).
Dysbiosis, or microbial imbalance, is being observed and studied in the
intestines of patients with IBD. A decreased ratio of protective commensal
species compared to aggressive species was observed in patients with IBD
2

(Frank et al., 2007). An increase in microbial number and a decrease in microbial
diversity have also been seen in patients with IBD (Sartor & Mazmanian, 2012).
However, it is not known whether the disease causes the dysbiosis or the
dysbiosis causes the disease. Although it is not known whether commensal
microbiota dysbiosis is a cause or effect of IBD, it can be inferred that microbial
dysbiosis can cause negative effects in patients by shifting the balance of the
patient’s flora in favor of harmful or proinflammatory microbial species. Therefore,
finding ways to correct this dysbiosis could be beneficial in the treatment, healing
process, and/or prevention of relapse of the disease.
In addition to microbial dysbiosis, short chain fatty acid (SCFA) levels are
lower than normal within the colon of a person with IBD (Huda-Faujan et al.,
2010; Kumari, Ahuja, & Paul, 2013). SCFAs are beneficial to the host and are
formed when dietary fiber is fermented in the colon. One particular SCFA,
butyrate, has been shown to be very beneficial to the health of the colon. It is an
important energy source to colonocytes and has been shown to inhibit
carcinogenesis and inflammation (McIntyre, Gibson, & Young, 1993; Andoh,
Bamba, & Sasaki, 1999). Butyrate has also been shown to enhance the colonic
defense barrier by stimulating increased mucin production (Finnie, Dwarakanath,
Taylor, & Rhodes, 1995). It also induces the differentiation of colonic regulatory T
cells, which could in turn contribute to the suppression of an inflammatory
response in the host (Furusawa et al., 2013). Therefore, increasing levels of
butyrate would seem to benefit a person with IBD, and this could be achieved
directly or indirectly by introducing butyrate producing bacteria or altering the
3

colonic environment in favor of the growth of butyrate producing bacteria by
giving the patient prebiotics.
Currently, there is no cure for IBD, and the only treatments for the disease
are anti-inflammatory and immunosuppressant drugs. These drugs can be
detrimental to human health and can lead to harmful side effects such as severe
toxicity, decrease in immune function, and increased risk of contracting
opportunistic infections. Therefore, other forms of treatment are urgently needed.
The uses of antibiotics, probiotics, and prebiotics have been studied as possible
treatments for IBD. Probiotics and prebiotics are more natural forms of treatment
that lack negative side effects, hence their appeal.
Broad spectrum antibiotics have been shown, in some cases, to benefit
patients with Crohn’s disease (Lal & Steinhart, 2006). However, they are not
known to be able to keep the disease under control and do not appear to be
effective against ulcerative colitis (Sartor, 2004). In addition, it is well known that
prolonged use of antibiotics can contribute to the development of resistant
bacteria, and the antibiotics can kill some of the beneficial microbiota in the
intestines. Probiotics, on the other hand have been shown to prevent recurrence
of intestinal inflammation and treat IBD with no dangerous side effects in a
limited number of studies (Dieleman et al., 2003; Gionchetti et al., 2000). A study
by Venturi et al. (1999) on patients with ulcerative colitis showed that probiotics
allowed 75% of the treated patients to remain in remission. Kruis et al. (2004)
also reported maintenance of remission in patients with IBD by using the
probiotic Escherichia coli Nissle 1917. Although probiotics can maintain
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remission of IBD, a mechanism of action of the probiotics has not been found.
Suggested mechanisms include preventing invasion by harmful bacteria,
improving epithelial and/or mucosal barrier, and altering the control of the
immune response (Sartor, 2004).
Another form of possible therapy for IBD, which has only recently begun to
be studied, is prebiotics. Prebiotics are carbohydrates incorporated into the diet
but are indigestible by the host. They cannot be absorbed until they reach the
colon, where they are fermented by certain commensal bacteria to produce short
chain fatty acids (SCFAs) and lactate (Scaldaferri et al., 2013). Short chain fatty
acid concentrations are reduced in the fecal contents of patients with IBD
(Packey & Sartor, 2008). Therefore, the supplementation of prebiotics into the
diet of a patient with IBD can be beneficial in helping to restore the SCFA
concentration to that of a normal person. Prebiotics also stimulate the growth of
beneficial and protective commensal bacteria that can help lower the number of
harmful bacteria by decreasing the luminal pH, preventing epithelial attachment,
and secreting bactericidal substances (Sartor, 2004). Although it can be seen
that prebiotics have tremendous potential as a treatment for the disease, they
“have not been adequately tested yet in IBD” (Sartor, 2004).
The idea of synbiotics, which combines the use of probiotics and
prebiotics, has become very appealing recently. This approach could speed up
recovery or decrease the duration or frequency of probiotic administration due to
synergy between probiotic and prebiotic treatments. This would lead to a
decrease in costs and an increase in patient readiness to accept it as a form of
5

treatment. Neither probiotics nor prebiotics have been approved as a reputable
form of treatment for IBD due to a lack of consistent evidence supporting the idea
that they work. Although several studies have been done to show the positive
effect of probiotics and prebiotics in the treatment of IBD, there is still much more
to be done before they can be considered as serious forms of treatment.
Specifically, the role of the prebiotic inulin has not been studied in preventing
relapse and maintaining remission in IBD (Kelly, 2009).
The objective of this research is to determine whether prebiotics improve
healing and enhance resistance to recurrence of IBD in mice, and if so, to
describe possible mechanisms for this. The hypothesis I propose to test is that
prebiotics promote the proliferation of butyrate producing gut bacteria in the colon
and that the increased production of butyrate stimulates an anti-inflammatory
immune response by increasing the differentiation of regulatory T cells. If this
beneficial environment remains within the colon, the immune system of the
mouse should prevent the reoccurrence of or, at least, mitigate the disease.
In order to test my hypothesis I planned to use a chemically induced
mouse model of colitis. After inducing inflammation, the mice would be treated
with prebiotics then allowed an extended period of recovery or healing before
reintroducing them to the chemical (DSS) that induces colitis. The physiological
and immunological response would be examined in the mice by looking at body
weight change, colon length, histology of the colon, and regulatory T cell counts
in the spleen. The fecal bacterial community would also be sequenced and
analyzed for each mouse, and the community would be searched for changes in
6

abundance of specific known butyrate producing bacteria. In support of my
hypothesis, it would be expected that with an increase in butyrate producing
bacteria, an increase in regulatory T cells should be observed. This increase in
regulatory T cells should then correlate with an increase in body weight and
colon length when compared to DSS control groups, as well as a decrease in
damage to the colon.
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CHAPTER II - METHODS
Mice and Experimental Treatment
All animal procedures were approved by the University of Southern
Mississippi IACUC Committee (Protocol Numbers 13121204 and 15120901).
Female mice (BALB/c) (six-eight weeks old) from Jackson Laboratory were
housed under standard conditions in shoebox cages with filter tops, with a twelve
hour photoperiod, and received a standard mouse diet (Teklad Global Soy
Protein-Free Extruded Rodent Diet (Sterilizable)) and unrestricted access to
water. Fourteen groups of mice were made (n=3 for each group), and mice were
weighed before the implementation of DSS (Dextran Sulfate Sodium) treatment.
On the first day of experimentation, ten of the fourteen groups of mice were given
3% DSS (MW~ 36,000-50,000) (MP Biomedicals, Cat. No. 160110) ad libitum, in
autoclaved H2O to chemically induce colitis in the mice. The 3% DSS solution
was sterilized by filtration (0.22 μm) before use. This supplementation into the
drinking water continued for four days total. Mice were weighed and observed
once daily for water/food consumption, stool consistency, and blood in the feces
after the start of DSS treatment. The remaining four groups of mice (control
groups) were given autoclaved water only during this time. After the four day
supplementation of DSS, mice were given autoclaved drinking water for three
days, then two groups of mice were euthanized by standard CO 2 inhalation
euthanasia, including one control group and one DSS treated group.
On Day 7 of the study, three groups of DSS treated mice received a daily
supplement of the prebiotic inulin (NOW Certified Organic Inulin, Code 2944B)
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(3% w/v) suspended in their autoclaved drinking water ad libitum. Another three
groups received the prebiotic Oligofructose Enriched Inulin (OEI) (PrebiotinTM)
(3% w/v) suspended in their autoclaved drinking water ad libitum. Both solutions
were filter sterilized through a 0.22 um filter before use. The remaining six groups
were given autoclaved drinking water during this time. This supplementation
lasted for two weeks. After the two week period was over, four groups of mice,
including one control group, one DSS group, one inulin treated group, and one
OEI treated group were euthanized. The remaining eight groups of mice were
given autoclaved drinking water for four more weeks. When the four week period
was over, four groups of mice, including one control group, one DSS group, one
inulin treated group, and one OEI treated group were euthanized. The remaining
four groups of mice were given a low concentration (1.5%) of DSS in autoclaved
drinking water ad libitum for four days to attempt to reactivate the colitis. They
were given autoclaved drinking water for three more days then euthanized.
This entire experiment was then repeated once more exactly, except that
inulin supplementation was no longer used.
Assessment of Disease State
Mouse body weight was measured every day during DSS treatment, and
weight loss was used to help determine disease severity. Fecal occult blood tests
were carried out by using a ColoScreen-ES test kit (Helena Laboratories, Cat.
No. 5086). Presence of blood in the feces indicated that the DSS had caused
intestinal inflammation, leading to bleeding. After euthanasia, the colon of each
mouse was harvested, and their lengths were measured. Differences in length of
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the colons indicated damage done by the DSS. The shorter the colon was, the
more damage was assumed (Kim, Shajib, Manocha, & Khan, 2012).
Flow Cytometry
Whole spleens were collected from mice on the day of euthanasia and
placed in five ml of RPMI-1640 + 10% fetal bovine serum (FBS) on ice. Each
spleen was crushed between two microscope slides and the released cells
suspended in the same medium. Cells were spun down at 500 X g for five
minutes, and supernatant was removed. Red blood cells were lysed by resuspending the cells in one ml of 1X Red blood cell lysis buffer (Sigma, Cat. No.
R7757) for five minutes. After stopping cell lysis by adding nine ml of 1X
phosphate-buffered saline (PBS) + 2% FBS, the cells were pelleted again by
centrifugation. The supernatant was again removed and the cells, resuspended
in 1X PBS + 2% FBS, were filtered through a 70 μm cell strainer to remove
cellular or tissue debris. The cells were pelleted one more time and then
resuspended in five ml of 1X PBS + 2% FBS for counting using a hemocytometer
and light microscope.
Once counted, cells were diluted with 1X PBS + 2% FBS to reach
approximately one million total cells per one ml. An Fc block was performed by
adding 0.5 μl of Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc block) (BD
Biosciences, Cat. No. 553141) for 10 minutes at 4°C, to prevent the staining of
cells other than T lymphocytes, such as B cells, monocyte/macrophages, natural
killer cells, and neutrophils. Cells were washed with 500 μl of PBS + 2% FBS and
spun down at 500 X g for five minutes. After discarding the supernatant, cells
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were resuspended in 20 μl of 1X PBS + 2% FBS, 2.5 ul of FITC (Anti-Mouse
CD3e) (eBioscience, Ref. No. 11-0031-85) and 0.75 μl of APC-eFluor 780 (AntiMouse CD4) (eBioscience, Ref No. 47-0041-82). Cells were allowed to incubate
for one hour at 4°C in the dark. After incubation, cells were washed two times
with 1X PBS + 2% FBS, and supernatant was discarded. The pellet was then
resuspended in 500 μl of 1X Fix/Permeabilization working solution from Foxp3
staining buffer set (eBioscience, Ref. No. 00-8333-56). This was incubated for 40
minutes at 4°C in the dark. Cells were spun down and then washed twice with
500 μl of 1X permeabilization buffer from Foxp3 staining buffer set. Cells were
resuspended in 20 μl of 1X permeabilization buffer and 2.5 μl of APC (AntiMouse/Rat Foxp3) (eBioscience, Ref. No. 17-5773-82) and allowed to incubate
for one hour at 4°C in the dark. Cells were washed twice with 1X
permeabilization buffer, resuspended in 1X permeabilization buffer, stored
overnight at 4°C in the dark, and observed the next day. Using a BD
LSRFortessa flow cytometer, 10,000 events were recorded. Live cells were gated
off using the Forward-scattered light (FSC) and Side-scattered light (SSC) plots,
and only live populations were observed and used for counting. The percentage
of Foxp3+ cells recorded was the percentage of live cells that were CD3+, CD4+,
and Foxp3+.
Feces Collection and DNA Extractions
One fecal pellet was collected from each mouse individually immediately
before euthanasia. Fecal pellets were stored individually in 1.5 ml sterile micro
centrifuge tubes at -20°C until DNA extraction. Fecal DNA extraction was
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performed using a PowerSoil DNA extraction kit (MO BIO Laboratories, Cat. No.
12888-100) and the manufacturer’s protocol. DNA concentration was measured
using a NanoDrop ND-1000 Spectrophotometer and the DNA stored at -20°C
until needed.
Fixing, Embedding, and Staining the Colon
After harvesting the colons, they were rolled into a Swiss roll formation,
placed in 10% neutral buffered formalin, and allowed to fix for 48 hours at 4°C.
The tissues were then dehydrated sequentially starting in 50% ethanol for two
hours, 70% ethanol overnight, and 95% ethanol for two hours, followed by three
changes of 100% ethanol for one hour each. To prepare samples for wax
infiltration and sectioning, ethanol was replaced with xylene by first placing
samples in a 1:1 solution of ethanol:xylene for one hour and then two changes of
100% xylene for one hour each. Samples were then moved to an oven set at
35°C, and paraffin wax chips were added slowly every two hours until the wax
stopped melting. The samples were then transferred to an oven set at 60°C,
where half of the paraffin/xylene mixture was poured out and replaced with
already melted paraffin from the oven. This addition of fresh paraffin happened
every two hours and was allowed to sit overnight after a complete change of
paraffin to allow complete infiltration.
Samples were then imbedded in molds in Paraplast plus paraffin for
sectioning at 10 um. The sections were then mounted on glass slides and
warmed at 30°C until they underwent hematoxylin and eosin staining. To begin
the staining process, slides were immersed in two changes of xylene for five
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minutes each to dewax the slides. Samples were then rehydrated by two
changes of 100% ethanol and two changes of 95% ethanol at three minutes
each. Slides were rinsed with distilled water for three minutes, then stained with
Richard-Allan Scientific Hematoxylin (Thermo scientific, Ref. No. 7211) for one
minute and 40 seconds. Slides were later immersed in clarifier (VWR
differentiation RTU, Cat. No. 95057-856) for one minute and 30 seconds followed
by a rinse step in distilled water for one minute. The slides were then placed in
bluing solution (VWR bluing reagent RTU, Cat. No. 95057-852) for 30 seconds
and rinsed again with distilled water for one minute followed by staining in Eosin
(VWR Phloxie-eosine, Cat. No. 95057-846) for 20 seconds. Samples were then
dehydrated again by passing through 95% ethanol for one minute, two changes
of 100% ethanol for two minutes each, and two changes of xylene for two
minutes each. Coverslips were then applied onto each slide using mounting
medium Permount, and the slides cured on a hot plate overnight at 60°C.
Assessment of Histological Damage
An unbiased observer scored each histological slide by using a previously
published scoring system, including scores for the following: crypt architecture
(normal, 0 - severe crypt distortion with loss of entire crypts, 3), degree of
inflammatory cell infiltration (normal, 0 – dense inflammatory infiltrate, 3), muscle
thickening (base of crypt sits on the muscularis mucosae, 0 – marked muscle
thickening present, 3), goblet cell depletion (absent, 0 – present, 1) and crypt
abscess (absent, 0 – present, 1) (Cooper, Murthy, Shah, & Sedergran, 1993; Kim
et al., 2012). The final histological damage score was the sum of each individual
13

score. The number of lymphoid aggregates was also counted for each sample.
Representative images were taken for each histological sample using a Leica
MC170 HD camera and a Leica DM IL light microscope. Examples of histological
images that display muscle thickening and crypt loss or distortion after induction
of colitis can be seen in Figure 2.
16S rRNA Illumina Sequencing
The gut microbial community of each mouse was assessed by sequencing
the V3-V4 region of the bacterial 16S rRNA gene extracted from fecal samples
from the first experiment. Sequencing was performed by the core sequencing
facility at the University of Mississippi Medical Center, Jackson MS in both
directions using Illumina MiSeq. The following forward and reverse primers were
used to amplify the V3-V4 region:
16S-F:
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
16S-R:
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC
Only full length, quality filtered, and overlapped reads were used in the
sequencing data analysis.
Sequence Analysis
The FASTX-Toolkit (version 0.0.14) was used to trim sequences of their
primers. In USEARCH (version 8.1.1825), a similarity threshold of 97% was used
in assigning operational taxonomic units (OTUs) as well as for removing
14

chimeras. Sequences were classified at the genus level using the Ribosomal
Database Project (RDP) (version 11.4) (Wang, Garrity, Tiedje, & Cole, 2007) with
default parameters. Classified sequences with their respective counts were
exported into Microsoft Excel 2013 and used to construct bar graphs of relative
abundances of 16s rRNA genes. R software package (version 3.2.3) was used to
determine significant indicator OTUs from each treatment group, and the
indicator OTUs were classified at the lowest level of classification possible using
RDP (version 11.4) (Wang et al., 2007) with default parameters.
Data Analysis
Graph Pad Prism (Version 6) was used to analyze and make figures from
all data from flow cytometry and histological scoring methods. Significance
(*P<0.05, **P<0.01, and ***P<0.001) was determined by unpaired parametric t
tests with Welch’s correction and a 95% confidence level.
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CHAPTER III - RESULTS
Body Weight Change
The body weight of mice with induced colitis decreased abruptly on Day 5
of treatment (Figure 1a). After the reintroduction of 1.5% DSS to cause relapse of
colitis in the mice, the DSS and inulin treatment groups showed a gradual loss of
body weight (Figure 1b), while the control groups and OEI treated groups
showed relatively stable body weight throughout treatment and a sharp increase
in body weight on Day 7 (Figure 1b).

16

Effect of Induced Colitis and Prebiotic Treatments on Mouse Body
Weight
Mean body weight change (%) in mice from (a) after 3% DSS treatment and (b) after reintroduction of 1.5% DSS. Error
bars indicate standard error of the mean (SEM).
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Histological Images

Effect of Induced Colitis on Microscopic Anatomy of the Colon
Representative images of colon sections from control mouse (a) and mouse after induced colitis (b). The arrow points out
areas of crypt damage or loss, while the star points out muscle thickening.

Colon Length
Colon length was significantly shortened in mice with induced colitis
(Figures 3a and b). Treatment with OEI led to longer colon length than those
treated with DSS alone (Figure 3b). After the reintroduction of 1.5% DSS to
stimulate relapse in the mice, the inulin treated group had significantly shorter
colon length than both the control and DSS treated groups (Figure 3d). In
contrast, the colon length in the OEI treated group was significantly longer than
that of the DSS treated group (Figure 3d).
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Effect of Induced Colitis and Prebiotic Treatments on Colon Length
Colon length measurements (mm) from (a) after 3% DSS treatment (b) after inulin and/or OEI prebiotic treatments (c)
after four week recovery period and (d) after reintroduction of 1.5% DSS. Error bars indicate SEM (n=6 for all groups
except DSS+Inulin, in which n=3). Significance (*P<0.05, and ***P<0.001) was determined by unpaired parametric t tests
with Welch’s correction and a 95% confidence level.

Histological Scores
DSS treated groups had higher histological scores than control groups
(Figures 4a, b, c, and d). However, this increase was not found to be significant.
Although the change was not significant, when compared to the DSS treated
groups, the OEI treated groups showed less histological damage overall,
specifically directly after prebiotic treatment (Figure 4b). In contrast, the inulin
treatment group showed a significantly higher histological score after the four
week recovery period (Figure 4c) and higher scores than the control, DSS, and
OEI treated groups after the reintroduction of 1.5% DSS, though this difference
was not significant (Figures 4b and d).

Effect of Induced Colitis and Prebiotic Treatments on Histological
Scores of the Colon
Histological scoring of colon sections (a) after 3% DSS treatment (b) after inulin and OEI prebiotic treatments (c) after four
week recovery period and (d) after reintroduction of 1.5% DSS. Error bars indicate SEM (n=6 for all groups except
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DSS+Inulin, in which n=3). Significance (*P<0.05) was determined by unpaired parametric t tests with Welch’s correction
and a 95% confidence level.

Lymphoid Aggregate Count
The number of lymphoid aggregates was higher in mice treated with DSS
initially, though this was not significant (Figure 5a). However, the number was
lower in DSS treated mice after relapse when compared to healthy controls
(Figure 5d). The count was higher in the prebiotic treated groups than control and
DSS treatment groups after the four week recovery period and the reintroduction
of DSS (Figures 5c and 5d). Furthermore, the count in the OEI treated group
after the four week recovery period was significantly higher than the control
group (Figure 5c).

Effect of Induced Colitis and Prebiotic Treatments on Lymphoid
Aggregate Counts in the Colon
Lymphoid aggregate count in histological sections from (a) after 3% DSS treatment (b) after inulin and OEI prebiotic
treatments (c) after four week recovery period and (d) after reintroduction of 1.5% DSS. Error bars indicate SEM (n=6 for
all groups except DSS+Inulin, in which n=3). Significance (*P<0.05) was determined by unpaired parametric t tests with
Welch’s correction and a 95% confidence level.
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Regulatory T cell Quantification
Induced colitis led to a significant increase in the number of Foxp3+ Treg
cells (Figure 6a). After prebiotic treatment, the number of Foxp3+ Treg cells was
higher in the DSS treatment group than in the control group and increased even
more in the OEI treatment group (Figure 6b). The number of Foxp3+ Treg cells
was significantly lower in the inulin treatment group when compared to the
control, DSS, and OEI treatment groups (Figure 6b). Treg cell number was
significantly lower in DSS treated and OEI treated groups after the four week
recovery period when compared to control mice (Figure 6c). However, after the
reintroduction of 1.5% DSS to induce relapse, the number of Foxp3+ Treg cells
was significantly increased in the inulin and OEI treatment groups when
compared to the control group and DSS treatment group (Figure 6d). This
significance was greater in the OEI treatment group than the inulin treatment
group (Figure 6d).

Effect of Induced Colitis and Prebiotic Treatments on Regulatory T cell
counts in Mouse Spleen
Percentage of FoxP3+ cells from total live cell population from (a) after 3% DSS treatment (b) after inulin and OEI
prebiotic treatments (c) after four week recovery period and (d) after reintroduction of 1.5% DSS. Error bars indicate SEM
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(n=6 for all groups except DSS+Inulin, in which n=3). Significance (*P<0.05, **P<0.01, and ***P<0.001) was determined
by unpaired parametric t tests with Welch’s correction and a 95% confidence level.
Note: Results from the first experiment four week healing period are not shown due to unreliable measurements (n=3 for
figure 6c).

Fecal Bacterial Community Composition
Overall, there was a relative increase in the number of Barnesiella spp.
from 37% to 51.62% in the DSS treated group and decrease in Anaeroplasma
spp. from 22.97% to 0.72% when compared to control mice (Figure 7a). The
proportion of Clostridium cluster XIVa spp. and Clostridium cluster XVIII spp. was
increased from 4.52% to 8.81% and from 0.06% to 3.3% respectively in the DSS
treated group when compared to controls (Figure 7a).
After prebiotic treatment, there was a relative increase in Barnesiella spp.
in the inulin (70.3%) and OEI (63.75%) treatment groups when compared to the
control (45.07%) and DSS (43.04%) treatment groups (Figure 7b). Relative
abundance of Clostridium cluster XIVa spp. was increased from 4.7% in the
control group to 10.29% in DSS, 6.97% in inulin, and 9.14% in OEI treatment
groups, while the abundance of bacteria belonging to Lactobacillus spp. were
decreased overall in the three groups (Figure 7b). An increase in abundance of
Lachnospiracea_incertae_sedis spp., Flavonifractor spp., Oscillibacter spp., and
Ruminococcus spp. was observed in the DSS treated group, while these groups
were closer to levels seen in the control group or lower in number in the inulin
and OEI treated groups (Figure 7b).
After the four week recovery period, relative abundance of Anaeroplasma
spp., Clostridium sensu stricto spp., Lachnospiracea_incertae_sedis spp., and
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Oscillibacter spp. was increased in the DSS treatment group while abundance of
these groups was decreased or closer to control levels in the inulin and OEI
treated groups (Figure 7c). Ruminococcus spp. were completely absent in DSS,
inulin, and OEI treated groups while Turicibacter spp. were only found in DSS
and OEI treated groups (Figure 7c). The relative proportion of Flavonifractor spp.
was increased in DSS and OEI treated groups (Figure 7c). Barnesiella spp.
numbers were decreased in DSS when compared to the control group and
increased in the inulin and OEI treatment groups (Figure 7c). Abundance of
Lactobacillus spp. was decreased in DSS and inulin treatment groups, while its
abundance was closer to control levels in the OEI treatment group (Figure 7c).
Finally, the proportion of Clostridium cluster XIVa spp. was decreased from
16.74% in the control group to 9.41% in the DSS group and 1.06% in the inulin
treated group. However, the proportion was closer to that of the control group in
the OEI treated group, being 12.48% (Figure 7c).
Following the reintroduction of 1.5% DSS, proportions of Barnesiella spp.,
Clostridium cluster XVIII spp., Enterococcus spp., and Escherichia/Shigella were
increased in DSS, inulin, and OEI treatment groups (Figure 7d). Numbers of
Clostridium cluster XIVa spp. and Oscillibacter spp. were lower in DSS, inulin,
and OEI treatment groups than in the control group (Figure 7d). The relative
abundance of Flavonifractor spp. was seen to be decreased in the DSS group
but restored to abundance similar to that of the control group in the inulin and
OEI treatment groups (Figure 7d). Lachnospiracea_incertae_sedis spp.
abundance was decreased in DSS and inulin treated groups and restored to
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abundance similar to the control group in the OEI treatment group (Figure 7d).
Lactobacillus spp. were seen in higher numbers in DSS and inulin treated
groups, but were observed in lower numbers than the control group in OEI
treated mice (Figure 7d). Ruminococcus spp. numbers were decreased in DSS
treated mice but were increased in inulin and OEI treated mice (Figure 7d).
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Effect of Induced Colitis and Prebiotic Treatments on the Fecal Bacteria
Composition at the Genus Level
Composition of the V3-V4 region of 16s rRNA counts at the genus level. (a) after 3% DSS treatment (b) after inulin and
OEI prebiotic treatments (c) after four week recovery period and (d) after reintroduction of 1.5% DSS. Each bar represents
the average composition of the three samples within each treatment group (n=3). No error bars are shown. Unclassified
bacteria are not shown.
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CHAPTER IV - DISCUSSION
Studies have shown that numbers of butyrate producing bacteria are
decreased in patients with IBD (Frank et al., 2007; Machiels et al., 2013). This
lack of potential butyrate production could be the cause of the reoccurrence of
inflammation. Butyrate has been shown to increase protein production in
colonocytes (Frankel et al., 1994). It has been shown to reduce the translocation
of bacteria across epithelium that was metabolically stressed (Lewis et al., 2010).
Butyrate has also been shown to stimulate mucin production in the colon (Finnie
et al., 1995) and induce the differentiation of colonic regulatory T cells, which are
critical in maintaining homeostasis in the intestine (Furusawa et al., 2013).
Therefore, the number of butyrate producing bacteria in an organism could
potentially directly correlate with the number of regulatory T cells in the organism.
By attempting to increase the abundance of butyrate producing bacteria in the
gut through the introduction of prebiotics, we attempt to increase the number of
regulatory T cells in the organism as well. The beneficial effects of butyrate
mentioned above, as well as an increase in regulatory T cell number, should
allow for an enhanced healing process in the diseased mice as well as a reduced
chance of relapse.
When measuring percent body weight change in the mice after the initial
introduction of 3% DSS (Figure 1a) and the reintroduction of 1.5% DSS (Figure
1b), the mice treated with 3% DSS began to lose weight around Day 5 of DSS
treatment, which was to be expected due to the inflammation in the guts of the
mice. When observing the body weight changes after the prebiotic treatments
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and reintroduction of DSS, the DSS and inulin treated groups (Figure 1b) had a
more significant decrease in body weight during the 1.5% DSS treatment than
the control or OEI treated groups had. The OEI treated group was more resistant
to the decrease in body weight, as it maintained levels similar to the control
group.
After induction of colitis, the colon length of the DSS treated mice was
shorter than the control mice (Figure 3a) and the histological score was higher in
the DSS treated mice (Figure 4a). This shortening of the colon and higher
histological score indicated the presence of inflammation in the colon (Kim et al.,
2012). The shortening of the colon and high histological scoring was even more
severe in the inulin treated mice (Figures 3d, 4c, and 4d). Overall, the OEI
treated groups exhibited less severe inflammation than the DSS or inulin treated
groups (Figures 3b, 3d, and 4b). The histological scores of the OEI treated group
were lowest directly after prebiotic treatment (Figure 4b) indicating a possible
enhanced healing process in these prebiotic treated mice.
A correlation has been shown between an increase in the number of
lymphoid aggregates and severity of colonic inflammation (Nascimbeni et al.,
2005). However, the role of these lymphoid aggregates in an inflamed colon may
actually be beneficial. Lymphoid aggregates have been shown to facilitate the
healing of intestinal injury by increasing cell proliferation in the intestinal
epithelium (Saxena, Thompson, & Sharp, 1997). Mice treated with DSS had
higher counts of lymphoid aggregates than the control mice during the first three
time points (Figures 5a-c). However, after relapse, the lymphoid aggregate
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counts were lower in DSS treated mice than in control mice (Figure 5d). Mice
treated with the prebiotic OEI had higher lymphoid aggregate counts than DSS
treated mice during two time points (Figures 5c and d). The increase in lymphoid
aggregates in the OEI treated mice could have caused the lowering in
histological score for this group of mice by allowing increased cell proliferation
and a faster healing response. A combination of an increase in the number of
lymphoid aggregates and an increase in the number of regulatory T cells could
further improve the healing process.
The number of Foxp3+ regulatory T cells was initially increased in the
spleens of DSS treated mice (Figures 6a and b) when compared to the control
group. This initial slight increase in regulatory T cells could be due to the immune
system of the mouse trying to prevent excessive inflammation in the gut. Since
the method of inducing colitis in the mice was chemically induced, the mice had
fully functioning immune systems. Therefore, it is not surprising that their immune
systems initially increased the production and/or differentiation of regulatory T
cells in order to attempt to attenuate the inflammation. However, the number of
regulatory T cells in the DSS treated mice after healing (Figure 6c) was
significantly lower than in the control group. This signifies that the regulatory T
cell response was not sustained in these animals or that it was down regulated at
some point. In contrast, the number of regulatory T cells in the OEI treatment
group after the reintroduction of DSS was significantly higher than in the control
or DSS treated groups (Figure 6d). This significant increase in regulatory T cells
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in the OEI treatment group could have contributed to the decrease in
inflammation in this group when compared to DSS treated controls.
Sequencing data was analyzed and classified at the genus level in order
to attempt to identify possible butyrate producing genera of bacteria. When
analyzing the gut bacterial community directly after introduction of 3% DSS, an
increase in potentially beneficial bacteria, such as Lactobacillus spp., and
possible butyrate producing bacteria, such as Clostridium cluster XIVa spp, was
observed. This contradicts earlier studies by Wang et al. (2014), Sokol et al.
(2009), and Takaishi et al. (2008) that showed an increase in Lactobacillus spp,
but a decrease in the Clostridium cluster XIVa group in human patients with
active IBD. The reason for the increase in potential butyrate producing bacteria
such as Clostridium cluster XIVa in mice treated with DSS is unknown. However,
it may be due to the mouse’s immune system trying to compensate for the
damage in the colon by increasing the likelihood of survival for beneficial bacteria
capable of producing butyrate, which can be used by colonocytes as an energy
source for tissue repair. The idea of altering gut microbial diversity through
immune regulation has been shown in a study by Kawamoto et al. (2014). In this
study, regulatory T cells were shown to regulate the secretion of immunoglobulin
A, which, in turn, regulated the diversity of species of bacteria within the intestine
(Kawamoto et al., 2014). The regulatory T cells in their study specifically
facilitated the selection and diversification of the Firmicutes phyla, and more
specifically, bacteria belonging to Clostridium clusters IV and XIVa (Kawamoto et
al., 2014).
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After the four week healing period and the reintroduction of DSS, the
abundance of this potentially beneficial Clostridium cluster XIVa group was lower
in DSS treated mice than in the control group (Figures 7c and d). Therefore, the
higher level of butyrate producing bacteria could not be maintained in the mouse
gut, probably due to prolonged inflammation and an altered environment within
the gut. Clostridium cluster XIVa spp. were nearly absent after the four week
healing period in the inulin treated mice. However this group was found to be
higher in abundance in the OEI treatment group than the DSS treatment group
and was nearly the same as the level found in the control group of mice at this
time point. The OEI treatment must have altered the environment within the colon
in favor of the conservation of this Clostridium group, either by directly feeding
the bacteria or by feeding other beneficial bacteria that produce side products,
such as lactic acid, that the Clostridium species have been shown to utilize in
their production of butyrate (Louis & Flint, 2009). The OEI prebiotic stimulated an
increase in Clostridium cluster XIVa bacteria from the time in which it was
administered to the time right before the reintroduction of DSS. The maintenance
of this potential butyrate producing group of bacteria could have led to the
increase in the expansion of regulatory T cells that was seen after the
reintroduction of DSS (Figure 6d). The increase in regulatory T cell number could
in turn allow the Clostridium group to be proliferated and diversified in favor of the
production of even more butyrate.
After reintroduction of DSS (Figure 7d) an outgrowth of
Escherichia/Shigella occurred in one mouse from each of the following groups:
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DSS, DSS+Inulin, and DSS+OEI. This signifies that recurrent use of DSS in a
mouse model may induce an environment that favors the overgrowth of certain
species of bacteria that can be adherent or invasive. However, the age of the
mice could have caused this outgrowth as well. Langille et al., (2014) showed
that the gut community is constantly changing in an aging mouse, so this should
be taken into consideration when observing the gut community of older mice.
Also, it should be noted that neither the body weight of the mice nor the feces
looked abnormal or different than the other mice that underwent the same 1.5%
DSS treatment. There were no signs of infection in the mice.
Significant indicator organisms were identified for each treatment group.
These OTUs were individually classified at the lowest level of classification
possible. A majority of the significant OTUs in each treatment group were only
identified down to the family level. Therefore, without having classified these
bacteria, we have no real way of knowing what role they may be playing in the
gut during these time points. Even with the abundant amount of sequencing data
we have, a majority of the bacterial species within the gut are still unclassified.
Some of the OTUs found could possibly be important in the healing process and
could potentially be used as probiotics if properly studied. In addition, some of
the indicator OTUs found in the DSS treated mice may be key in triggering or
maintaining inflammation in the gut, and if we could identify them, we could
possibly learn how to control them.
Most sequencing analyses done on mice treated with DSS have only
identified bacteria at the phylum level with some being identified down to the
35

family level. However this level of identification is not deep enough to distinguish
between beneficial and potentially pathogenic bacteria, nor to identify potential
butyrate producing bacteria in a community. The studying of changes at the
genus level mainly occurs in human studies and have not been thoroughly
examined in mice. This study attempts to classify bacteria down to the genus
level in order to identify possible butyrate producing groups in the mice.
Future directions may include sampling the mucosal associated bacterial
community rather than the fecal community. The mucosal associated community
has been shown to be significantly different from the fecal community. Van den
Abbeele et al. (2013) found that Bacteroidetes and Proteobacteria dominated the
luminal content of an in vitro gut model, while Firmicutes, specifically bacteria
from Clostridium cluster XIVa, were more abundant in the mucin layer of the gut.
Therefore, the butyrate producing bacteria may actually be more abundant in the
mucosal associated tissue in order to enhance butyrate production near the
tissue and site of inflammation itself to enhance its repair and regeneration (Van
den Abbeele et al., 2013). More drastic or significant changes in the bacterial
community of the gut may be seen if the mucosal community is studied rather
than the fecal community.
Another study that could be done is to measure the number of regulatory
T cells in the colon during the different time points and see if the number of cells
is increased there as well after prebiotic treatment. Knowing that there is an
increase in regulatory T cells in the blood and spleen after prebiotic treatment is
a good start, but we also need to determine if these cells are migrating to the
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colon where the inflammation is occurring and where they need to be active. One
last future direction may be to determine how much butyrate is actually being
taken up and utilized by the colonocytes. Ahmad et al. (2000) showed that
butyrate oxidation by colonocytes is impaired in mice with DSS induced colitis.
Therefore, increasing levels of butyrate in the gut through the use of prebiotics is
a good start to treating IBD. However, we need to figure out how to repair the
damaged colonocytes more quickly and efficiently so they can utilize the excess
butyrate available to them. A combination of corticosteroids and prebiotics could
possibly be used. Corticosteroids could decrease the inflammation enough to
help put the patient in a state of remission and help colonocytes be able to
function properly and utilize butyrate. The dampening of inflammation could also
allow for the microbial community to return to a somewhat normal state, and the
prebiotic supplementation would ensure that the butyrate producing community is
present to provide energy to the colonocytes. A consistent use of prebiotics could
possibly help the patient remain in remission.
In conclusion, I propose that when inflammation occurs in the gut, an
environmental change takes place within the gut that allows for beneficial
butyrate producing bacteria to be outcompeted. When this happens, the
colonocytes cannot receive proper amounts of butyrate for energy to repair and
replace themselves, and further inflammation may occur. If the proper microbial
balance within the gut is not restored, by the use of prebiotics for example, this
inflammation can becoming a recurring event and lead to inflammatory bowel
disease. Through the use of prebiotics, we can ensure that the butyrate
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producing bacteria of the gut have a food source from which they can produce
butyrate, which in turn will give colonocytes the energy to allow them to
reproduce more quickly and allow more rapid healing of the inflamed gut. OEI is
a particular prebiotic that shows promising results in this study by inducing the
proliferation of butyrate- producing bacteria which led to the increase in
regulatory T cell production and down regulation of inflammation in diseased
mice. Therefore, this prebiotic should be studied in more detail in the future.
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